Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs"

NCT03339102 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03339102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03339102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs"
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
January 25, 2018
Completion date
July 16, 2020
Enrollment
158 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

non-infectious intermediate, posterior and panuveitis